Adabi Zahra, Mohsen Ziaei Seyed Amir, Imani Mahdieh, Samzadeh Mohammad, Narouie Behzad, Jamaldini Seyed Hamid, Afshari Mahdi, Safavi Majid, Roshandel Mohammad Reza, Hasanzad Mandana
Medical Genomics Research Center, Tehran Medical Sciences Branch, Islamic Azad University, Tehran, Iran.
Urology and Nephrology Research Center (UNRC), Shahid Labbafinejad Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Arch Med Res. 2015 Oct;46(7):546-50. doi: 10.1016/j.arcmed.2015.08.004. Epub 2015 Aug 28.
The polymorphic genetic variants of matrix metalloproteinase (MMPs) can play critical roles in development and progression of cancer. The purpose of this study was to investigate if any association exists between MMP2 -1306/T and risk of prostate cancer (PCa).
This case-control study comprised a total number of 241 subjects, including 102 patients with PCa and 139 controls with benign prostatic hyperplasia (BPH). MMP2 genotypes were detected by RFLP.
There is no significant difference between different genotypes of MMP2 polymorphism and risk of developing PCa (p = 0.08). Although these genotypes increased the risk of developing PCa 79% (CT vs. CC) and 54% (TT vs. CC), none had a significant effect (p = 0.09 and p = 1 respectively). There were no significant differences in genotype frequencies between patients with low and high degrees of PCa (p = 0.4). Therefore, this polymorphism cannot be considered as a protective factor for PCa metastasis. It seems that MMP2 polymorphism has no protective effect on the grading of the tumor (p = 0.8). Our results indicated that MMP2 polymorphism had no role in the vascular invasion of PCa.
We found no association between MMP2 polymorphism and cancer risk, overall or by grade, stage or age of diagnosis. Finally, there was no association between the different genotypes and PSA plasma levels among cases or controls. Further evaluations with larger samples from our population may illuminate the effects of polymorphisms on PCa risk and thus help early diagnosis, follow-up and prognostic determinations for PCa patients.
基质金属蛋白酶（MMPs）的多态性基因变异在癌症的发生和发展中可能起关键作用。本研究的目的是调查MMP2 -1306/T多态性与前列腺癌（PCa）风险之间是否存在关联。
本病例对照研究共纳入241名受试者，包括102例PCa患者和139例良性前列腺增生（BPH）对照。通过限制性片段长度多态性（RFLP）检测MMP2基因型。
MMP2多态性的不同基因型与发生PCa的风险之间无显著差异（p = 0.08）。尽管这些基因型使发生PCa的风险分别增加了79%（CT vs. CC）和54%（TT vs. CC），但均无显著影响（p分别为0.09和1）。低度和高度PCa患者之间的基因型频率无显著差异（p = 0.4）。因此，这种多态性不能被视为PCa转移的保护因素。似乎MMP2多态性对肿瘤分级无保护作用（p = 0.8）。我们的结果表明MMP2多态性在PCa的血管侵袭中无作用。
我们发现MMP2多态性与总体癌症风险以及按诊断分级、分期或年龄分组的癌症风险之间均无关联。最后，病例组或对照组中不同基因型与血浆前列腺特异抗原（PSA）水平之间无关联。对我们人群中更大样本的进一步评估可能会阐明多态性对PCa风险的影响，从而有助于PCa患者的早期诊断、随访和预后判定。
